Program
deupsilocin
Its studies are mostly in Depressive Disorder, Major, led by Cybin IRL.
Furthest: phase 3, since Aug 20, 20243 company-led studies, 2 open or runningNext primary completion: Jun 7, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cybin IRL | 32 open or running | phase 3since Aug 20, 2024 | Aug 20, 2024 | Jun 7, 2027phase 3 · NCT06793397 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 20, 2024First study: phase 3 study in Depressive Disorder, MajorFirst studyNCT06564818 · 223 enrolled · United States
- Sep 16, 2024Phase 3 study in Depressive Disorder, MajorNCT06605105 · 468 planned · United States, Australia, Greece and more
- Jan 21, 2025Phase 3 study in Depressive Disorder, MajorNCT06793397 · 330 planned · United States, Australia, Czechia and more
Ahead
- Jun 7, 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT06793397
- Jun 6, 2028Primary completion: phase 3 study in Depressive Disorder, MajorNCT06605105
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06793397Depressive Disorder, Major · United States, Australia, Czechia and more | 3 | Recruiting | Jun 7, 2027 | 330 |
| NCT06605105Depressive Disorder, Major · United States, Australia, Greece and more | 3 | By invitation | Jun 6, 2028 | 468 |
| NCT06564818Depressive Disorder, Major · United States | 3 | Completed | Sep 4, 2026 | 223 |
How it is read
Names in the registry
- “CYB003”, 3 entries
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.